Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PTGFR | P43088 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 2/20 | 0.38 |
| ▸ | PGK2 | P07205 | 2/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915502 | 0.83 | PGK1 (0.50) | ACP3PGK1PGK2PTPN1 | |
| SCHEMBL29616518 | 0.83 | PGK1 (0.50) | ACP3PGK1PGK2PTPN1 | |
| SCHEMBL2863591 | 0.79 | CTRC (0.50) | CTRCALOX5TBXA2RPTGER4PTGFR | |
| SCHEMBL2864769 | 0.78 | SLC5A2 (0.45) | PGK1PGK2PTPN5SMN1; SMN2 | |
| SCHEMBL2863444 | 0.78 | TP53 (0.44) | — | |
| SCHEMBL2873192 | 0.78 | SLC5A2 (0.49) | PTPN5 | |
| SCHEMBL2868009 | 0.77 | ALOX5 (0.50) | CTRCALOX5TBXA2RPTGER4PTGFR | |
| SCHEMBL9170574 | 0.76 | PGK1 (0.50) | ACP3PGK1PGK2 | |
| SCHEMBL2874055 | 0.76 | SLC5A2 (0.51) | — | |
| SCHEMBL2865155 | 0.75 | SLC5A1 (0.48) | ACP3PGK1PGK2PTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691898-B2 | Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-101072783-A | Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-11-14 | — | — | CN | disclosed |
| EP-1813620-A1 | PHOSPHONIC ACID DERIVATIVE AND THERAPEUTIC AGENT FOR DISEASE IN WHICH HIGH PHOSPHATE LEVEL IN BLOOD PARTICIPATES | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | NR0B1, NR0B2, PTH1R | CTRC 1976/4885ALOX5 427/4885TBXA2R 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.